Navigation Links
Study of successful drug targets could hasten development of new medications
Date:1/31/2008

Guidance from an innovative computational approach could speed up the process and cut down the cost of new drug development, researchers from the University of Chicago Medical Center and Columbia University suggest in a study to be published in the February 2008 issue of Genome Research, available early online.

The researchers analyzed specific properties of the human genes and proteins that serve as targets for nearly a thousand FDA-approved drugs. They identified a number of characteristics that were common among successful drug targetsand especially common among high-revenue drugs.

"To make a good drug, you need to find a good drug target," said Andrey Rzhetsky, PhD, professor of medicine at the University of Chicago and senior author of the study. "Here we provide guidelines for more efficient target screening. When a drug company must decide which target to pursue among pathologic pathways, this could provide useful estimates of each target's expected success rate."

Gleevec, Prozac, Viagra: these successful drugs all target specific proteins and provoke a desired response. They reward the people who need them, as well as to those who invent, manufacture and market them.

But he development of a new drug is complicated and expensive, "a fusion of art and science," the authors note. It involves finding an accessible drug target and a molecule that binds that target as selectively as possible. Then it must trigger a desirable physiological change.

But "every highly visible success," the authors note, "rests on an iceberg of invisible failures." Since the estimated cost of developing a new drug ranges from $800 million to $1.2 billion, "information that helps only a little bit," Rzhetsky said, "can still be quite valuable."

What characteristics, they asked, distinguished the targets that eventually became the focus of such successful drugs" How are these genes or proteins different from the tens of thousa
'/>"/>

Contact: John Easton
John.Easton@uchospitals.edu
772-702-6241
University of Chicago Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Conservation strategies must shift with global environmental change, says CU-Boulder study
2. Virginia Tech plant scientist leads study on genomics of parasitic plants
3. Smithsonian study: Sediment prediction tools off the mark
4. Prison study to investigate link between diet and behavior
5. Queens study connects obesity with nervous system
6. LSU, Yale team study agricultural impact on Mississippi River
7. Diet and lifestyle critical to recovery, says study
8. Scientists study the link between childrens nutrition and adult diseases
9. New Argonne study may shed light on protein-drug interactions
10. Sea otter study reveals striking variability in diets and feeding strategies
11. Study: weight-loss tips differ in African-American, mainstream magazines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... one per eight hundred births, Down syndrome - or ... of intellectual disability. It results from a chromosomal abnormality ... of chromosome 21 (1% of the human genome). A ... the Department of Genetic Medicine and Development at the ... Nature , shed light on how the extra ...
(Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
(Date:4/17/2014)... are implicated in many serious conditions such as heart ... target for drug therapies. Unfortunately, there is still much ... research provides fresh and unexpected insight into the structure ... - β-subunit molecules - which are responsible for ,fine-tuning, ... in the most recent edition of the Journal ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2Structure of sodium channels different than previously believed 2
... Researchers at Northwestern University have developed a new ... providing an alternative that is more flexible and ... describing the results, "Low-Pressure Foaming: A Novel Method ... Engineering," was featured in the February issue of ...
... and Shenzhen, China BGI, the world,s largest ... Research Center located in Copenhagen Bio Science Park ... meters and equipped with 10 Illumina HiSeq 2000 ... better accelerate the innovation and development of genomics ...
... ON., Feb. 10, 2012--St. Michael,s Hospital and King Saud University ... BRCA1 gene as a therapy for cardiovascular disease. Dr. ... Mohammed Al-Omran, a vascular surgeon at the largest university in ... 110,185 B2 issued Feb. 7. Obtaining the patent is ...
Cached Biology News:Researchers develop new method for creating tissue engineering scaffolds 2BGI opens genome research center in Europe 2BGI opens genome research center in Europe 3
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... March 25 Trubion Pharmaceuticals, Inc. (Nasdaq: ... Pharmaceuticals, a division of Wyeth (NYSE: WYE ... SBI-087, Trubion,s next generation CD20 drug candidate, for the ... Small Modular ImmunoPharmaceutical (SMIP(TM)) technology, SBI-087 is also being ...
... PHILADELPHIA, March 25 In an economic environment ... Prime Health Network and its patients are thriving ... industry leading healthcare payments network and platform, Prime ... their costs related to collections, while also improving ...
... a privately held biotechnology company focused on developing novel ... sindbis viral vector, today announced that Frank Stonebanks, President ... National Venture Conference in Boston on Wednesday, April 1, ... LLC , Cynvec, a privately held biotechnology company, ...
Cached Biology Technology:Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE) 2Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE) 3Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network 2Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network 3
...
... with Annexin V-FITC to distinguish cells that ... (Annexin V positive, PI negative) from those ... or already dead (Annexin V-FITC positive, PI ... range of the spectrum using a 562-588 ...
... RPMI 1640 with 2 mM L-glutamine and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... is a software package that provides ... for custom buffer creation, set-up of ... crystallization trials. The software helps crystallographers ... automated protein crystallography: ...
Biology Products: